Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRCLNASDAQ:LIANNASDAQ:PHXMNASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRCLGracell Biotechnologies$10.25$10.25$1.40▼$10.44$744.95M-0.331.32 million shsN/ALIANLianBio$0.38+2.6%$0.27$0.27▼$4.99$41.01M0.231.04 million shs25,076 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AZBIOZenas Biopharma$9.97-3.5%$9.97$5.83▼$26.25$432.15MN/A188,044 shs137,567 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRCLGracell Biotechnologies0.00%0.00%0.00%0.00%0.00%LIANLianBio0.00%+2.24%-0.11%+90.80%+17.24%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%ZBIOZenas Biopharma-3.48%-16.36%-4.78%+26.20%+996,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRCLGracell BiotechnologiesN/AN/AN/AN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZBIOZenas Biopharma1.2856 of 5 stars3.50.00.00.01.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRCLGracell Biotechnologies 0.00N/AN/AN/ALIANLianBio 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/AZBIOZenas Biopharma 3.00Buy$36.67267.77% UpsideCurrent Analyst Ratings BreakdownLatest GRCL, ZBIO, LIAN, and PHXM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ZBIOZenas BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025ZBIOZenas BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$35.003/20/2025ZBIOZenas BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$35.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRCLGracell Biotechnologies$60K12,415.83N/AN/A$2.95 per share3.47LIANLianBioN/AN/AN/AN/A$2.71 per shareN/APHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39ZBIOZenas Biopharma$15M27.81N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRCLGracell Biotechnologies-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/ALIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/AZBIOZenas BiopharmaN/A-$3.55N/A∞N/AN/AN/AN/A8/21/2025 (Estimated)Latest GRCL, ZBIO, LIAN, and PHXM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ZBIOZenas Biopharma-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRCLGracell BiotechnologiesN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AZBIOZenas Biopharma$0.050.48%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRCLGracell Biotechnologies0.027.737.73LIANLianBioN/A10.0610.06PHXMPHAXIAM Therapeutics0.231.78N/AZBIOZenas BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRCLGracell BiotechnologiesN/ALIANLianBio74.85%PHXMPHAXIAM Therapeutics0.40%ZBIOZenas BiopharmaN/AInsider OwnershipCompanyInsider OwnershipGRCLGracell Biotechnologies28.00%LIANLianBio7.59%PHXMPHAXIAM Therapeutics1.94%ZBIOZenas Biopharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRCLGracell Biotechnologies31472.68 million52.33 millionOptionableLIANLianBio110108.06 million99.86 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataZBIOZenas BiopharmaN/A41.83 millionN/AN/AGRCL, ZBIO, LIAN, and PHXM HeadlinesRecent News About These CompaniesInvestors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)June 16 at 6:30 PM | accessnewswire.comZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 16 at 4:00 PM | globenewswire.comZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineJune 16 at 1:25 PM | globenewswire.comJune 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & KorsinskyJune 16 at 12:40 PM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 16 at 12:10 PM | accessnewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 16 at 11:00 AM | businesswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 16 at 10:15 AM | accessnewswire.comZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 16 at 9:07 AM | prnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025 DeadlineJune 16 at 7:31 AM | accessnewswire.comFINAL REMINDER ZBIO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Zenas BioPharma, Inc. Investors to Participate in the Class Action LawsuitJune 16 at 7:00 AM | accessnewswire.comJune 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIOJune 16 at 5:45 AM | prnewswire.comZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors - Lead Plaintiff Deadline June 16, 2025June 16 at 4:20 AM | accessnewswire.comFINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIOJune 16 at 3:44 AM | prnewswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 15 at 7:27 PM | accessnewswire.comZBIO IMPORTANT DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by The Firm - ZBIOJune 15 at 6:18 PM | accessnewswire.comZenas BioPharma, Inc. (ZBIO) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before June 16, 2025June 15 at 1:05 PM | accessnewswire.comZenas BioPharma, Inc. (ZBIO) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 16, 2025 DeadlineJune 15 at 11:00 AM | accessnewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 15 at 10:44 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 15 at 10:00 AM | globenewswire.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Zenas BioPharma, Inc. (ZBIO)June 15 at 8:05 AM | accessnewswire.comZenas Biopharma Inc (NASDAQ:ZBIO) Shares Sold by Wellington Management Group LLPJune 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsRH Stock Rockets on Surprise Profit and Tariff ShiftBy Chris Markoch | June 15, 2025View RH Stock Rockets on Surprise Profit and Tariff ShiftGRCL, ZBIO, LIAN, and PHXM Company DescriptionsGracell Biotechnologies NASDAQ:GRCLGracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.LianBio NASDAQ:LIAN$0.38 +0.01 (+2.57%) As of 06/13/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 06/13/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Zenas Biopharma NASDAQ:ZBIO$9.97 -0.36 (-3.48%) As of 06/16/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
